In this downloadable slideset, expert faculty members Andrew Carr, MBBS, MD, FRACP, FRCPA; Daniel R. Kuritzkes, MD; and Ian M. Sanne, MBBCH, FCP(SA), review key studies presented at the 2016 International AIDS Conference.
Format: Microsoft PowerPoint (.ppt)
File size: 1.28 MB
Date posted: 8/5/2016
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...hivlifeinfo
Clinical Impact of New Data From CROI 2017
Expert faculty members Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File size: 1.25 MB
Date posted: 3/3/2017
Современное лечение ВИЧ: когда начинать, чем начинать. Contemporary Managemen...hivlifeinfo
.Contemporary Management of HIV. When to Start, What to Start.2016/Современное лечение ВИЧ: когда начинать, чем начинать.
In this downloadable slideset, Daniel R. Kuritzkes, MD, and Program Director Eric S. Daar, MD review key data and optimal approaches for first-line ART with contemporary HIV regimens.
Format: Microsoft PowerPoint (.ppt)
File size: 2.53 MB
Date posted: 2/9/2016
Clinical Impact of New HIV Data From the 2016 Comorbidities-Adverse Drug Reac...hivlifeinfo
In this downloadable slideset, expert faculty members Todd T. Brown, MD, PhD, and Jordan E. Lake, MD, MSc, review key studies presented at the 2016 Comorbidities/Adverse Drug Reactions Workshop.
Format: Microsoft PowerPoint (.ppt)
File size: 1.37 MB
Date posted: 10/14/2016
Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...hivlifeinfo
In this downloadable slideset, Kathleen E. Squires, MD, and Program Director Joseph J. Eron, Jr., MD, review key data and optimal strategies in caring for HIV-infected women, including ART safety and efficacy in women, reproductive health management, ART and pregnancy, and preventing HIV infection in women.
Format: Microsoft PowerPoint (.ppt)
File size: 1.59 MB
Date posted: 4/25/2017
Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017hivlifeinfo
Top Advances in ART for 2017
In this downloadable slideset, Joel E. Gallant, MD, MPH, provides a comprehensive update on ART management.
Format: Microsoft PowerPoint (.ppt)
File size: 579 KB
Date posted: 3/29/2017
Современное лечение ВИЧ: лечение многократно леченных пациентов с резистентно...hivlifeinfo
This document discusses management of HIV in heavily treatment-experienced patients with multiclass resistance and limited treatment options. It provides an overview of the problem, including that some older patients were treated early in the HIV epidemic with less potent regimens, resulting in resistance. Younger patients may have congenital HIV and been treated long-term. Assessment of virologic failure and resistance testing are important to select an effective new regimen. Current options for active drugs in these patients include maraviroc, ibalizumab, fostemsavir, and enfuvirtide, which have novel mechanisms of action. Adherence assessment is also critical to determine if the current regimen may still be effective if taken as prescribed.
Современное лечение ВИЧ: новые подходы к оптимизации АРТ/Contemporary Managem...hivlifeinfo
Вопросы, связанные с АРТ первого ряда, смена арв-стратегии для пациентов с вирусной супрессией, акцентом на возрастающую роль новыхантиретровирусных стратегий.
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...hivlifeinfo
Clinical Impact of New Data From CROI 2017
Expert faculty members Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File size: 1.25 MB
Date posted: 3/3/2017
Современное лечение ВИЧ: когда начинать, чем начинать. Contemporary Managemen...hivlifeinfo
.Contemporary Management of HIV. When to Start, What to Start.2016/Современное лечение ВИЧ: когда начинать, чем начинать.
In this downloadable slideset, Daniel R. Kuritzkes, MD, and Program Director Eric S. Daar, MD review key data and optimal approaches for first-line ART with contemporary HIV regimens.
Format: Microsoft PowerPoint (.ppt)
File size: 2.53 MB
Date posted: 2/9/2016
Clinical Impact of New HIV Data From the 2016 Comorbidities-Adverse Drug Reac...hivlifeinfo
In this downloadable slideset, expert faculty members Todd T. Brown, MD, PhD, and Jordan E. Lake, MD, MSc, review key studies presented at the 2016 Comorbidities/Adverse Drug Reactions Workshop.
Format: Microsoft PowerPoint (.ppt)
File size: 1.37 MB
Date posted: 10/14/2016
Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...hivlifeinfo
In this downloadable slideset, Kathleen E. Squires, MD, and Program Director Joseph J. Eron, Jr., MD, review key data and optimal strategies in caring for HIV-infected women, including ART safety and efficacy in women, reproductive health management, ART and pregnancy, and preventing HIV infection in women.
Format: Microsoft PowerPoint (.ppt)
File size: 1.59 MB
Date posted: 4/25/2017
Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017hivlifeinfo
Top Advances in ART for 2017
In this downloadable slideset, Joel E. Gallant, MD, MPH, provides a comprehensive update on ART management.
Format: Microsoft PowerPoint (.ppt)
File size: 579 KB
Date posted: 3/29/2017
Современное лечение ВИЧ: лечение многократно леченных пациентов с резистентно...hivlifeinfo
This document discusses management of HIV in heavily treatment-experienced patients with multiclass resistance and limited treatment options. It provides an overview of the problem, including that some older patients were treated early in the HIV epidemic with less potent regimens, resulting in resistance. Younger patients may have congenital HIV and been treated long-term. Assessment of virologic failure and resistance testing are important to select an effective new regimen. Current options for active drugs in these patients include maraviroc, ibalizumab, fostemsavir, and enfuvirtide, which have novel mechanisms of action. Adherence assessment is also critical to determine if the current regimen may still be effective if taken as prescribed.
Современное лечение ВИЧ: новые подходы к оптимизации АРТ/Contemporary Managem...hivlifeinfo
Вопросы, связанные с АРТ первого ряда, смена арв-стратегии для пациентов с вирусной супрессией, акцентом на возрастающую роль новыхантиретровирусных стратегий.
Сравнение режимов лечения ВИЧ в разрезе различных клинических сценариев.ART...hivlifeinfo
This downloadable slideset summarizes optimal evidence-based antiretroviral therapy management strategies for a series of challenging clinical cases and is based on a satellite symposium presented at HIV Glasgow 2016.
Format: Microsoft PowerPoint (.ppt)
File size: 1.32 MB
Date posted: 11/11/2016
Contemporary Management of HIV.How Common Comorbidities Affect ART Management...hivlifeinfo
In this downloadable slideset, expert faculty review key data and offer important guidance on managing HIV treatment in patients with frequently encountered comorbidities, including cardiovascular disease, osteopenia, and HCV coinfection.
Format: Microsoft PowerPoint (.ppt)
File size: 2.27 MB
Date posted: 2/12/2018
Key Slides on Individualizing ART Management Based on Treatment Safety and To...hivlifeinfo
Обзор последних рекомендаций DHHS , индивидуализация лечения в отдельных группах пациентов, минимизация побочных эффектов и межлекарственных взаимодействий
This document discusses contemporary management of HIV with a focus on individualizing first-line antiretroviral therapy (ART). It provides an overview of recommended first-line ART regimens including integrase strand transfer inhibitors (INSTIs), discusses clinical trial data comparing different INSTI and protease inhibitor options, and considers factors in choosing among available single-tablet regimen options. It also addresses the potential roles of newer non-nucleoside reverse transcriptase inhibitors and tenofovir alafenamide versus tenofovir disoproxil fumarate in first-line ART.
Модификация схем АРТ у пациентов с вирусной супрессией и после вирусологичес...hivlifeinfo
This document discusses best practices for switching antiretroviral therapy (ART) regimens in virologically suppressed patients and after virologic failure. It provides an overview of reasons to consider switching ART in suppressed patients, such as improving tolerability or managing drug interactions. Principles of switching include reviewing resistance history and increasing viral load monitoring post-switch. Studies show switching from efavirenz-containing regimens can improve neurological side effects. Switching to newer regimens like dolutegravir or elvitegravir/cobicistat was found to maintain viral suppression in most patients.
Современное лечение ВИЧ.Усилить или не усилить : преимущества и недостатки бу...hivlifeinfo
Современное лечение ВИЧ.Усилить или не усилить : преимущества и недостатки бустированных режимов АРТ / Contemporary Management of HIV.To Boost or Not to Boost-Advantages and Disadvantages of Boosted ART.2017
In this downloadable slideset, Eric S. Daar, MD, and Program Director Joseph J. Eron, Jr., MD, review advantages and disadvantages of boosted ART regimens for managing patients with HIV.
Format: Microsoft PowerPoint (.ppt)
File size: 514 KB
Date posted: 6/16/2017
Ключевые слайды по индивидуальному выбору АРТ / Key Slides on Individualized ...hivlifeinfo
Слайды с последними данные и рекомендациями по выбору АРТ, как для пациентов, ранее не получавших лечения, так и пациентов с вирусологической супрессией. Оценки разных вариантов лечения, индивидуализация АРТ для женщин детородного возраста и во время беременности, пациентов с опортунистическими инфекциями и новые данные об исследовательских стратегиях АРТ.
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и ...hivlifeinfo
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и у пациентов с вирусологической неудачей. /Contemporary Management of HIV. Modifying Antiretroviral Therapy in Virologically Suppressed Patients and Those With Treatment Failure.2016
In this downloadable slideset, W. David Hardy, MD, and Program Director Eric S. Daar, MD review key data and optimal approaches for modifying ART in patients who are virologically suppressed or have experienced treatment failure.
Format: Microsoft PowerPoint (.ppt)
File size: 2.07 MB
Incorporating New ART Options Into First-line and Switch Strategies for HIV C...hivlifeinfo
This document discusses several new HIV treatment regimens approved between 2017-2019, including three-drug fixed-dose combinations of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF), and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DRV/COBI/FTC/TAF). Clinical trials showed BIC/FTC/TAF and DOR/3TC/TDF were
Современное лечение ВИЧ: АРТ у пациентов с сопутствующими заболеваниями.Conte...hivlifeinfo
Современное лечение ВИЧ:АРТ у пациентов с сопутствующими заболеваниями.//Contemporary Management of HIV. Managing ART in HIV-Infected Patients With Common Comorbidities. 2016
In this downloadable slideset, David A. Wohl, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for managing ART in the context of common comorbidities.
Format: Microsoft PowerPoint (.ppt)
File size: 3.51 MB
Начало АРТ впервые.Наилучшая практика.Best Practices in Antiretroviral Therap...hivlifeinfo
Best Practices in Antiretroviral Therapy: Initiating First-line Therapy
In this downloadable slideset, Charles B. Hicks, MD, discusses data on initiating antiretroviral therapy in HIV-infected patients.
Format: Microsoft PowerPoint (.ppt)
File size: 2.16 MB
HIV Alert:ART Considerations for Aging Patients.2018hivlifeinfo
In this downloadable slideset, Eric S. Daar, MD, and David A. Wohl, MD, provide expert recommendations for older patients with HIV, both in terms of ART selection and general management.
Format: Microsoft PowerPoint (.ppt)
File size: 545 KB
Date posted: 2/12/2018
Contemporary Management of HIV.How Aging Affects ART Management.2018hivlifeinfo
In this downloadable slideset, Expert Faculty review key data on managing aging patients with HIV.
Format: Microsoft PowerPoint (.ppt)
File size: 720 KB
Date posted: 3/7/2018
Современное лечение ВИЧ: новые парадигмы в АРТ / Contemporary Management of H...hivlifeinfo
Набор слайдов c рассмотрением важных вопросов об АРТ первого ряда, арв-препаратами пролонгированного действия и схемами АРТ с двумя препаратами, акцент в публикации на роль новых стратегий.
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...hivlifeinfo
This document discusses modifying antiretroviral therapy (ART) in virologically suppressed patients with HIV. It describes two phase 3 trials, ATLAS and FLAIR, that evaluated switching to long-acting injectable cabotegravir plus rilpivirine (CAB/RPV) every 4 weeks in suppressed patients. Both trials found CAB/RPV to be noninferior to continued oral ART at 48 weeks. Common reasons to consider an ART switch include simplifying regimens or improving tolerability. Key factors that may increase risk of treatment failure with CAB/RPV include presence of rilpivirine resistance mutations at baseline and lower rilpivirine drug levels. The FDA
Слайдсет о новом в лечении ВИЧ.Key Slides on What’s Hot in HIV Treatment.2020 hivlifeinfo
Expert-authored slides on the latest issues relating to HIV care, featuring patient cases and considerations for optimal treatment approaches. Topics include integrating newer ARVs, individualizing ART for women of childbearing potential and during pregnancy, adverse events during ART, and anticipated roles of emerging ART strategies.
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...Hivlife Info
In this downloadable slideset, Joseph J. Eron, Jr., MD, and Daniel Kuritzkes, MD, review key data on the evolving use of INSTIs in patients beginning HIV therapy.
Format: Microsoft PowerPoint (.ppt)
File size: 2.29 MB
Confronting the Challenges of HIV Care in an Aging Population.2019hivlifeinfo
Еxpert faculty use case-based examples to examine considerations for aging patients with HIV. Topics include ART modification, bone loss, renal impairment, cardiovascular risk, and cognitive decline.
АРТ в 2016-2017 гг: неизменная потребность в индивидуализации лечения для улу...hivlifeinfo
PB has several considerations for her antiretroviral regimen:
- She wants a single tablet regimen
- Her CD4+ count and viral load make her a good candidate for most regimens
- She has HCV genotype 1a infection
- She takes lovastatin for hyperlipidemia
The best regimen for PB would be:
- DTG/ABC/3TC as it is recommended for most patients, has few drug interactions, and does not interact with lovastatin.
Close monitoring of her liver function would be needed if she initiates HCV treatment in the future while on an antiretroviral regimen.
Сравнение режимов лечения ВИЧ в разрезе различных клинических сценариев.ART...hivlifeinfo
This downloadable slideset summarizes optimal evidence-based antiretroviral therapy management strategies for a series of challenging clinical cases and is based on a satellite symposium presented at HIV Glasgow 2016.
Format: Microsoft PowerPoint (.ppt)
File size: 1.32 MB
Date posted: 11/11/2016
Contemporary Management of HIV.How Common Comorbidities Affect ART Management...hivlifeinfo
In this downloadable slideset, expert faculty review key data and offer important guidance on managing HIV treatment in patients with frequently encountered comorbidities, including cardiovascular disease, osteopenia, and HCV coinfection.
Format: Microsoft PowerPoint (.ppt)
File size: 2.27 MB
Date posted: 2/12/2018
Key Slides on Individualizing ART Management Based on Treatment Safety and To...hivlifeinfo
Обзор последних рекомендаций DHHS , индивидуализация лечения в отдельных группах пациентов, минимизация побочных эффектов и межлекарственных взаимодействий
This document discusses contemporary management of HIV with a focus on individualizing first-line antiretroviral therapy (ART). It provides an overview of recommended first-line ART regimens including integrase strand transfer inhibitors (INSTIs), discusses clinical trial data comparing different INSTI and protease inhibitor options, and considers factors in choosing among available single-tablet regimen options. It also addresses the potential roles of newer non-nucleoside reverse transcriptase inhibitors and tenofovir alafenamide versus tenofovir disoproxil fumarate in first-line ART.
Модификация схем АРТ у пациентов с вирусной супрессией и после вирусологичес...hivlifeinfo
This document discusses best practices for switching antiretroviral therapy (ART) regimens in virologically suppressed patients and after virologic failure. It provides an overview of reasons to consider switching ART in suppressed patients, such as improving tolerability or managing drug interactions. Principles of switching include reviewing resistance history and increasing viral load monitoring post-switch. Studies show switching from efavirenz-containing regimens can improve neurological side effects. Switching to newer regimens like dolutegravir or elvitegravir/cobicistat was found to maintain viral suppression in most patients.
Современное лечение ВИЧ.Усилить или не усилить : преимущества и недостатки бу...hivlifeinfo
Современное лечение ВИЧ.Усилить или не усилить : преимущества и недостатки бустированных режимов АРТ / Contemporary Management of HIV.To Boost or Not to Boost-Advantages and Disadvantages of Boosted ART.2017
In this downloadable slideset, Eric S. Daar, MD, and Program Director Joseph J. Eron, Jr., MD, review advantages and disadvantages of boosted ART regimens for managing patients with HIV.
Format: Microsoft PowerPoint (.ppt)
File size: 514 KB
Date posted: 6/16/2017
Ключевые слайды по индивидуальному выбору АРТ / Key Slides on Individualized ...hivlifeinfo
Слайды с последними данные и рекомендациями по выбору АРТ, как для пациентов, ранее не получавших лечения, так и пациентов с вирусологической супрессией. Оценки разных вариантов лечения, индивидуализация АРТ для женщин детородного возраста и во время беременности, пациентов с опортунистическими инфекциями и новые данные об исследовательских стратегиях АРТ.
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и ...hivlifeinfo
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусной супрессией и у пациентов с вирусологической неудачей. /Contemporary Management of HIV. Modifying Antiretroviral Therapy in Virologically Suppressed Patients and Those With Treatment Failure.2016
In this downloadable slideset, W. David Hardy, MD, and Program Director Eric S. Daar, MD review key data and optimal approaches for modifying ART in patients who are virologically suppressed or have experienced treatment failure.
Format: Microsoft PowerPoint (.ppt)
File size: 2.07 MB
Incorporating New ART Options Into First-line and Switch Strategies for HIV C...hivlifeinfo
This document discusses several new HIV treatment regimens approved between 2017-2019, including three-drug fixed-dose combinations of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF), and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DRV/COBI/FTC/TAF). Clinical trials showed BIC/FTC/TAF and DOR/3TC/TDF were
Современное лечение ВИЧ: АРТ у пациентов с сопутствующими заболеваниями.Conte...hivlifeinfo
Современное лечение ВИЧ:АРТ у пациентов с сопутствующими заболеваниями.//Contemporary Management of HIV. Managing ART in HIV-Infected Patients With Common Comorbidities. 2016
In this downloadable slideset, David A. Wohl, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for managing ART in the context of common comorbidities.
Format: Microsoft PowerPoint (.ppt)
File size: 3.51 MB
Начало АРТ впервые.Наилучшая практика.Best Practices in Antiretroviral Therap...hivlifeinfo
Best Practices in Antiretroviral Therapy: Initiating First-line Therapy
In this downloadable slideset, Charles B. Hicks, MD, discusses data on initiating antiretroviral therapy in HIV-infected patients.
Format: Microsoft PowerPoint (.ppt)
File size: 2.16 MB
HIV Alert:ART Considerations for Aging Patients.2018hivlifeinfo
In this downloadable slideset, Eric S. Daar, MD, and David A. Wohl, MD, provide expert recommendations for older patients with HIV, both in terms of ART selection and general management.
Format: Microsoft PowerPoint (.ppt)
File size: 545 KB
Date posted: 2/12/2018
Contemporary Management of HIV.How Aging Affects ART Management.2018hivlifeinfo
In this downloadable slideset, Expert Faculty review key data on managing aging patients with HIV.
Format: Microsoft PowerPoint (.ppt)
File size: 720 KB
Date posted: 3/7/2018
Современное лечение ВИЧ: новые парадигмы в АРТ / Contemporary Management of H...hivlifeinfo
Набор слайдов c рассмотрением важных вопросов об АРТ первого ряда, арв-препаратами пролонгированного действия и схемами АРТ с двумя препаратами, акцент в публикации на роль новых стратегий.
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...hivlifeinfo
This document discusses modifying antiretroviral therapy (ART) in virologically suppressed patients with HIV. It describes two phase 3 trials, ATLAS and FLAIR, that evaluated switching to long-acting injectable cabotegravir plus rilpivirine (CAB/RPV) every 4 weeks in suppressed patients. Both trials found CAB/RPV to be noninferior to continued oral ART at 48 weeks. Common reasons to consider an ART switch include simplifying regimens or improving tolerability. Key factors that may increase risk of treatment failure with CAB/RPV include presence of rilpivirine resistance mutations at baseline and lower rilpivirine drug levels. The FDA
Слайдсет о новом в лечении ВИЧ.Key Slides on What’s Hot in HIV Treatment.2020 hivlifeinfo
Expert-authored slides on the latest issues relating to HIV care, featuring patient cases and considerations for optimal treatment approaches. Topics include integrating newer ARVs, individualizing ART for women of childbearing potential and during pregnancy, adverse events during ART, and anticipated roles of emerging ART strategies.
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...Hivlife Info
In this downloadable slideset, Joseph J. Eron, Jr., MD, and Daniel Kuritzkes, MD, review key data on the evolving use of INSTIs in patients beginning HIV therapy.
Format: Microsoft PowerPoint (.ppt)
File size: 2.29 MB
Confronting the Challenges of HIV Care in an Aging Population.2019hivlifeinfo
Еxpert faculty use case-based examples to examine considerations for aging patients with HIV. Topics include ART modification, bone loss, renal impairment, cardiovascular risk, and cognitive decline.
АРТ в 2016-2017 гг: неизменная потребность в индивидуализации лечения для улу...hivlifeinfo
PB has several considerations for her antiretroviral regimen:
- She wants a single tablet regimen
- Her CD4+ count and viral load make her a good candidate for most regimens
- She has HCV genotype 1a infection
- She takes lovastatin for hyperlipidemia
The best regimen for PB would be:
- DTG/ABC/3TC as it is recommended for most patients, has few drug interactions, and does not interact with lovastatin.
Close monitoring of her liver function would be needed if she initiates HCV treatment in the future while on an antiretroviral regimen.
PrEP Update from the International HIV Treatment, Prevention, and Adherence C...Office of HIV Planning
Jen Chapman, Co-Chair of the Philadelphia HIV Prevention Planning Group (HPG) presented an update from the 10th annual International HIV Treatment, Prevention, and Adherence conference at the July 2015 HPG meeting.
Calculating Member Cost Sharing for Pharmacy ClaimsJohn Long
The document discusses challenges in calculating member pharmacy costs for health insurance plans. It describes how chronic conditions often require significant pharmacy utilization, but medications may not be covered by plans or may be on high-cost tiers. The Medicare Part D Plan Finder tool aims to help members find low-cost plans but has limitations. State health exchange data is available for some plans but may not provide full details needed. Calculating costs accurately is challenging due to issues like combined deductibles, drug pricing differences between pharmacies, and modeling non-formulary drugs.
Aetna care pass challenge webinar 8.1.12health2dev
This document provides information about the Aetna CarePass Developer Challenge, which aims to develop mobile applications to improve medication adherence. It introduces Aetna CarePass and the need for medication reminder solutions. The challenge will award $75,000 to the first place winner and $25,000 to the second place winner for developing an app that allows users to enter medications and receive reminders to take them. The app is also encouraged to provide medication cost information and integrate with the Aetna CarePass platform. The submission deadline is August 17th and winners will be announced in October.
Improvement in adherence to HAART: Best practices in adherence education by t...CDC NPIN
The document summarizes a study that evaluated adherence education interventions by three AIDS service organizations (ASOs). It found that all three interventions significantly improved clients' HIV disease management knowledge, experience taking medications, viral load, CD4 count, and perceived health over multiple time periods. The interventions incorporated individual counseling, peer support, medication education, and incentives. Characteristics of the populations served and details of each ASO's intervention approach are provided.
Americans and hiv aids - selected 2014 national survey findings from the kais...KFF
The document summarizes findings from two 2014 surveys by the Kaiser Family Foundation regarding Americans' awareness and knowledge of HIV/AIDS. Some key findings include: over half of respondents know someone living with or who died from HIV/AIDS; HIV/AIDS is rarely or never discussed with family or intimate partners for many; and less than 40% of respondents were aware of major scientific advances in HIV treatment and prevention. The surveys found that while most had been tested for HIV at some point, relatively few reported getting tested regularly as advised.
Humana is a large health benefits company that provides coverage to 7 million medical members and over 2 million dental members across the United States. It has implemented an enterprise data warehouse that integrates data from various sources and provides business intelligence capabilities. The data warehouse stores over 4.3 billion rows of information from medical claims, pharmacy claims, web logs, and other sources. It supports a variety of business functions including utilization reporting, financial analysis, underwriting, customer reporting, and health management programs. The data warehouse enables Humana to gain insights, innovate new offerings, manage costs and risks, and tailor support to members' health needs.
ВИЧ-инфекция у женщин : стратегии 3 ключевых глобальных проблем.2016.HIV In...hivlifeinfo
ВИЧ-инфекция у женщин : стратегии 3 ключевых глобальных проблем.2016.HIV Infection Among Women- Strategies to Address 3 Key Global Challenges .2016
In this downloadable slideset, Catherine Hankins, MD, PhD, FRCPC, CM, reviews current global challenges for HIV-infected women and explores methods for HIV prevention and ART delivery, particularly in resource-limited settings.
Format: Microsoft PowerPoint (.ppt)
File size: 1.03 MB
Date posted: 9/1/2016
The document contains statistics about the disproportionate impact of HIV/AIDS on gay and bisexual men and black Americans. It shows that while gay and bisexual men make up only 2% of the US population, they account for 55% of HIV infections and 58% of people currently living with HIV. It also shows that black Americans, who make up 12% of the population, account for 41% of AIDS deaths and 43% of current HIV infections.
Improving Adherence in HIV Treatment with Once-Daily TherapiesDocKretschmar
1. Several studies examined the relationship between adherence to antiretroviral drug regimens and virologic outcomes in HIV/AIDS patients. Simpler once-daily dosing was associated with improved adherence and clinical outcomes compared to more complex twice-daily regimens.
2. Other research showed that once-daily dosing of hypertension and diabetes medications led to better adherence rates and health outcomes over twice-daily administration.
3. The data supported transitioning select HIV-infected patients with undetectable viral loads on a twice-daily protease inhibitor regimen to a simplified once-daily regimen, which maintained viral suppression and improved CD4 counts in the majority of patients.
This document provides guidelines for antiretroviral therapy in Malaysia. It outlines contributors and reviewers, then covers goals of ART including reducing morbidity and mortality while improving quality of life. It discusses factors to consider when initiating ART, available drug classes and fixed dose combinations, guidelines for assessing newly diagnosed and experienced patients, and important laboratory tests for evaluation and monitoring during treatment.
This document discusses using analytics to optimize medication adherence interventions. It begins by introducing GNS Healthcare and their Meaningful Adherence solution, which uses predictive modeling to precisely match individuals to specific adherence interventions that will maximize the return on investment. It then provides examples showing how value-based selection identifies more individuals who could benefit from interventions compared to rules-based selection based solely on medication possession ratio. The document concludes by outlining GNS's approach and analytics platform for planning, implementing, and continuously optimizing population health management programs and adherence interventions.
The document promotes Walgreens' API program which allows developers to integrate their apps with Walgreens' 8,000+ stores and services. The API provides access to prescription refills and transfers, printing services to stores, and opportunities to increase customer engagement like photo cards. Developers are encouraged to use the API by signing up on the developer portal to gain an API key and onboarding assistance.
Chelsey Strand is a clinical review pharmacist at Prime Therapeutics in Edina, MN who reviews requests for insurance approval or denial based on plan criteria. She previously worked as a medication therapy management specialist and staff pharmacist at Walgreens pharmacies in Eden Prairie and Minneapolis, MN between 2007-2016. She holds a Doctor of Pharmacy degree from North Dakota State University and a pharmacy license in Minnesota.
HIV Alert: Best Practices in ART Following Recent Drug Approvals.2016hivlifeinfo
In this downloadable slideset, Eric S. Daar, MD, and Joel E. Gallant, MD, MPH, review best practices and provide expert opinion in using newly approved ART options for treating patients with HIV.
Format: Microsoft PowerPoint (.ppt)
File size: 816 KB
Date posted: 5/12/2016
D1 Highly Active Antiretroviral Treatment (HAART) DHHS Guidelines 2009 DuffusDSHS
The document discusses guidelines for initiating highly active antiretroviral treatment (HAART) based on CD4 count and viral load. Guidelines from 1998-2009 increasingly recommended treating HIV at higher CD4 counts and without a specific viral load threshold. Studies show the magnitude of CD4 increase is greatest when starting HAART at low counts, but normalization is more likely the earlier therapy begins. A CD4 count below 350 cells/mm3 increases the risk of cardiovascular and other non-AIDS complications.
Sexually Transmitted Diseases Management in HIV.2016hivlifeinfo
This document provides slides from a presentation on STD management in HIV. It includes slides on taking a 3-question sexual history, common STD treatments according to 2015 CDC guidelines, screening recommendations for HIV-positive patients, and more. The slides are meant to be used for non-commercial presentations and include disclosures that the presenter has no conflicts of interest.
Современное лечение ВИЧ.Обобщённые данные с конференции CROI 2020 / Contempor...hivlifeinfo
This document summarizes data presented at CROI 2020 on current and investigational antiretroviral therapies (ART) for HIV. Key findings include:
- A pooled analysis found the 3-drug regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) was effective and well-tolerated in people over age 50 similar to younger patients.
- The switch to BIC/FTC/TAF was noninferior to remaining on baseline regimens even in people with baseline nucleoside reverse transcriptase inhibitor resistance.
- Through week 96, dolutegravir plus lamivudine was similarly effective
Современное лечение и профилактика ВИЧ : передовые стратегии лечения у пациен...hivlifeinfo
Стратегии смены АРТ у пациентов с вирусной супрессией, включая смену АРТ при резистентности, рекомендации по инъекционным препаратам длительного действия , смена АРТ до или во время беременности
Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...Hivlife Info
In this downloadable slideset, Joseph J. Eron, Jr., MD and Jürgen K. Rockstroh, MD, review key HIV studies presented at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy, 2014 IDWeek, and 2014 HIV Drug Therapy Glasgow.
Format: Microsoft PowerPoint (.ppt)
File size: 1.70 MB
Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...hivlifeinfo
In this downloadable slideset, Joseph J. Eron, Jr., MD and Jürgen K. Rockstroh, MD, review key HIV studies presented at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy, 2014 IDWeek, and 2014 HIV Drug Therapy Glasgow.
Format: Microsoft PowerPoint (.ppt)
File size: 1.70 MB
FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive ...hivlifeinfo
March 4-7, 2019; Seattle, Washington
Higher patient-reported satisfaction with monthly injectable dual regimen compared with daily oral tablets.
Released: March 11, 2019
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...Hivlife Info
The document summarizes highlights from the 20th International AIDS Conference held in Melbourne, Australia in July 2014. It includes results from several clinical trials presented at the conference evaluating new antiretroviral regimens for initial therapy and treatment switches in suppressed patients. One study found maraviroc plus darunavir/ritonavir was not non-inferior to tenofovir/emtricitabine plus darunavir/ritonavir for initial therapy. Another study found switching suppressed patients to a dual regimen of lopinavir/ritonavir plus lamivudine or emtricitabine was non-inferior to continuing a triple regimen. A sub-
Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020hivlifeinfo
Expert-authored slides on evolving ART concepts, including simplification to 2-drug therapy, ART safety during pregnancy, weight gain, and long-acting injectable ART.
File Size: 580 KB
Released: October 20, 2020
GARDEL es un estudio multicéntrico internacional, diseñado por la Fundación Huésped que demostró que usando dos drogas se pueden obtener resultados similares al tradicional "coctel" con tres drogas. Esto permite tener una alternativa más simple, más económica y con menos efectos colaterales para los pacientes.
HIV Alert:Emerging Updates on Dual Therapy.2018hivlifeinfo
In this downloadable slideset, Joseph J. Eron, Jr., MD, and Babafemi Taiwo, MBBS, provide expert insight into the use of a recently-approved dual-therapy regimen and review data surrounding investigational two-drug regimens.
Format: Microsoft PowerPoint (.ppt)
File size: 375 KB
Date posted: 1/5/2018
This document summarizes a presentation on HIV treatment and prevention. Some key findings include:
1) Studies ATLAS and FLAIR found that two-drug regimens containing cabotegravir and rilpivirine were non-inferior to standard three-drug regimens in maintaining viral suppression. Patients preferred the long-acting injectable formulations.
2) A study of Biktarvy in children and adolescents found it was well-tolerated and maintained viral suppression, with pharmacokinetics similar to adults.
3) Pooled analyses found tenofovir alafenamide was associated with better renal and bone safety outcomes compared to tenofovir disoproxil
Основы ведения АРТ у многократно леченных пациентов 2022 / Foundations of ART...hivlifeinfo
Основы ведения АРТ у многократно леченных пациентов (2022)
Тактики ведения пациентов с большим опытом лечения, включая анализ резистентности, последние рекомендации и данные по новым схемам АРТ
HIV Alert:Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents ...hivlifeinfo
HIV Alert-Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents for HIV Management.2017
In this downloadable slideset, Daniel R. Kuritzkes, MD, and Paul E. Sax, MD, review potential future HIV treatment strategies—including dual-therapy regimens, long-acting ART, and investigational agents—and discuss where these might fit into the current therapeutic landscape.
Format: Microsoft PowerPoint (.ppt)
File size: 570 KB
Date posted: 9/27/2017
HIV Alert- Novel Strategies and Agents for HIV Management.2016hivlifeinfo
In this downloadable slideset, Daniel R. Kuritzkes, MD, and Paul E. Sax, MD, review potential future HIV treatment strategies—including long-acting ART, dual-therapy regimens, and investigational agents—and discuss where these strategies might fit into the current therapeutic landscape.
Format: Microsoft PowerPoint (.ppt)
File size: 926 KB
Date posted: 6/21/2016
Clinical Impact of New Data From AIDS 2020hivlifeinfo
current ART in principal populations, including older patients and women who become pregnant; metabolic outcomes during ART; HIV and COVID-19; investigational ART strategies; and HIV prevention.
This document provides an overview and summary of recent data on antiretroviral therapy (ART) for HIV. Key findings include:
- A study in Thailand found that daily oral tenofovir reduced HIV infection risk among injection drug users by 48.9%, leading to new guidelines recommending PrEP for high-risk drug users.
- US demonstration projects found high adherence to PrEP among at-risk populations, with tenofovir levels indicating protection.
- Multiple studies found dolutegravir to be superior to other regimens in suppressing HIV and had fewer side effects, establishing it as a preferred integrase inhibitor.
- No transmissions occurred in a large study of serod
This document provides an overview and summary of recent data on antiretroviral therapy (ART) for HIV. Key findings include:
- A study in Thailand found that daily oral tenofovir reduced HIV infection risk among injection drug users by 48.9%, leading to new guidelines recommending PrEP for high-risk drug users.
- US demonstration projects found high adherence to PrEP among at-risk populations, with tenofovir levels indicating protection.
- Multiple studies found dolutegravir to be superior to other regimens in treatment-naive patients, maintaining activity even at high viral loads.
- No transmissions occurred in a large study of serodiscordant couples where the
Clinical Impact of New Data From AIDS 2018hivlifeinfo
Clinical Impact of New Data From AIDS 2018
July 23-27, 2018; Amsterdam, The Netherlands
Expert faculty members summarize key studies from this important annual conference.
Modern European Guidelines on HIV Treatment 2016. Key Updateshivlifeinfo
This document summarizes key points from modern European guidelines on HIV treatment. It discusses factors to consider when deciding when to start antiretroviral therapy (ART) and which first-line regimen to use. Major studies like START and FLAMINGO provided evidence that immediate ART improves health outcomes and that dolutegravir is as effective as protease inhibitor-based regimens. Guidelines now recommend starting all patients on ART due to its prevention of HIV-related diseases and transmission. Tenofovir alafenamide (TAF) shows improved bone and kidney outcomes compared to tenofovir DF (TDF) in switch studies.
Doravirine/islatravir was found to be non-inferior to continuing bictegravir/F/TAF in maintaining viral suppression. Simplification to F/TDF following induction with INSTI + 2 NRTIs resulted in similar virologic suppression rates, CD4 gains, and changes in body weight compared to dolutegravir/3TC. Low-level viremia was associated with subsequent virologic failure in a dose-dependent manner. Causes of death in people with HIV have shifted from HIV/AIDS-related to non-AIDS cancers as treatment has improved and patients live longer.
Дискуссии о здоровом старении с ВИЧ /Key Slides on Healthy Aging With HIV.2022hivlifeinfo
Дискуссии о здоровом старении с ВИЧ
Узнайте о медицинских и немедицинских проблемах, с которыми сталкиваются стареющие пациенты с ВИЧ, включая дополнительные проблемы, с которыми сталкиваются пожилые женщины и пожилые люди, живущие в условиях ограниченных ресурсов.
Гиперлипопротеидемия(а) как опасное генетически обусловленное нарушение липид...hivlifeinfo
Гиперлипопротеидемия(а) как опасное генетически обусловленное нарушение липидного обмена и фактор риска атеротромбоза и сердечно-сосудистых заболеваний
Липопротеид(а) [Лп(а)] представляет собой сложный надмолекулярный комплекс, принадлежащий к апоВ100 содержащим липопротеидам. Лп(а) состоит из ЛНП-подобной частицы, в которой молекула апобелка В100 ковалентно связана дисульфидной связью с уникальной полиморфной молекулой апобелка(а). Концентрация Лп(а) генетически контролируется, при этом варьирует в очень широком диапазоне. Повышенный уровень Лп(а) является независимым фактором риска атеросклероза коронарных, сонных и периферических артерий, ИБС и стеноза аортального клапана, сопутствующих сердечно-сосудистых осложнений, а также осложнений после операций реваскуляризации миокарда. Несмотря на это, уровень Лп(а) по-прежнему не учитывается в стратификации риска сердечно-сосудистых заболеваний. Отчасти, это может быть связано с тем, что ни современная лекарственная терапия, ни новые поколения биологических гиполипидемических препаратовтерапия практически не влияют на концентрацию Лп(а), за исключением 20-30% снижения Лп(а) никотиновой кислотой и ингибиторами пропротеиновой конвертазы субтилизин-кексин 9 типа (PCSK9).
Лекция освящает современные представления о Лп(а), как факторе риска сердечно-сосудистых заболеваний, возможности и целесообразности его определения, а также посвящена современным возможностям коррекции гиперлипопротеидемии(а).
Физическая активность и физические тренировки как метод профилактики сердечно...hivlifeinfo
Чушкин М.И., Мандрыкин С.Ю., Карпина Н.Л., Попова Л.А. Физическая активность и физические тренировки как метод профилактики сердечно-сосудистых заболеваний. Кардиология. 2018;58(9S):10-18
Большое число данных свидетельствует, что функциональные возможности кардиореспираторной системы являются не менее важным фактором прогноза летальности, чем курение, артериальная гипертензия, ожирение, гиперхолестеринемия, СД. Пациенты с большей физической активностью имеют значительно меньший риск ССЗ, чем пациенты, ведущие неактивный образ жизни. В данном обзоре авторы показали возможности оценки физической активности и основные положения назначения физических тренировок для сохранения и повышения функциональных возможностей кардиореспираторной системы.
This document summarizes an expert panel discussion on innovative antiretroviral therapy (ART) paradigms. The panel discussed whether positive results from two-drug and long-acting injectable regimens in clinical trials will translate to long-term efficacy and safety. They also considered the potential risks of resistance emerging with two-drug regimens and the impact of missed doses with long-acting injectables. The panel agreed that maintaining cold storage requirements for long-acting injectables may pose challenges for implementation in low- and middle-income countries but that qualitative research found patients highly satisfied with the convenience of long-acting ART.
Свобода интернета 2018: делегирование репрессий.Доклад Международной Агорыhivlifeinfo
«Настоящий доклад посвящен обзору вмешательства в свободу интернета в России в 2018 году и основан на данных постоянного мониторинга ситуации, который мы ведем более 10 лет.
Как обычно, доклад состоит из двух основных разделов, первый из которых посвящен описанию результатов мониторинга с приведением наиболее показательных примеров, а второй – авторской оценке состояния свободы интернета. В приложении даны сводные результаты мониторинга в виде таблицы со ссылкой на дату, источник, регион и вид ограничения по каждому известному эпизоду, а также карта нарушений, на которой цветом обозначен уровень относительной свободы интернета в отдельных субъектах Федерации.»
https://guides.files.bbci.co.uk/bbc-russian/AGORA_Freedom-of-the-Internet-2018.pdf
Современное лечение ВИЧ.Объединенные данные с конференции IAS 2019 / Contemp...hivlifeinfo
Review key HIV data from IAS 2019 on the updated NTD risk in women receiving ART at conception, PrEP, first-line and switch options, and early-phase investigational strategies.
Clinical Impact of New Data From IAS 2019hivlifeinfo
July 21-24, 2019; Mexico City, Mexico
Download slide highlights of key studies addressing current issues in HIV care, as reported at this important annual conference.
Предиабет-определение, риски, подходы к диагностике и профилактике сахарного ...hivlifeinfo
Предиабет-определение, риски, подходы к диагностике и профилактике сахарного диабета 2 типа и сердечно-сосудистых осложнений.Консенсус экспертов РКО.2019
"Результаты международного эпидемиологического проекта HAPIEЕ показали, что распространенность преддиабета в Российской Федерации (РФ), определяемого по нарушенной гликемии натощак, может быть еще выше — от 28,1% при отрезной точке по уровню глюкозы плазмы ≥6,1 ммоль/л (критерий Российской ассоциации эндокринологов) до 54.8 % при при отрезной точке по уровню глюкозы плазмы ≥5,6 ммоль/л (критерий ADA), соответственно."
Tsepamo: DTG Exposure at Conception Associated With Smaller Increase in Incid...hivlifeinfo
This updated analysis of the Tsepamo birth outcomes surveillance study in Botswana found:
1) The prevalence of neural tube defects was slightly higher among women who conceived while receiving dolutegravir compared to other antiretroviral regimens, but lower than initially reported.
2) There was no significant difference in the risk of other major structural malformations or additional adverse birth outcomes between dolutegravir and efavirenz at conception.
3) Based on these updated findings, the WHO reconfirmed the use of dolutegravir-based antiretroviral therapy as the preferred first-line and second-line regimen.
Случаи и разногласия по ВИЧ в 2019 году: европейские перспективы / Cases and...hivlifeinfo
Learn unique perspectives across Europe on PrEP, rapid ART initiation, ART in women, and options for switching ART.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.33 MB
Released: July 10, 2019
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
DECLARATION OF HELSINKI - History and principlesanaghabharat01
This SlideShare presentation provides a comprehensive overview of the Declaration of Helsinki, a foundational document outlining ethical guidelines for conducting medical research involving human subjects.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
1. This activity is supported by an independent educational grant from
ViiV Healthcare
July 18-22, 2016
Durban, South Africa
Highlights of AIDS 2016
CCO Official Conference Coverage
of the 21st International AIDS Conference
In partnership with
2. Slide credit: clinicaloptions.com
About These Slides
Please feel free to use, update, and share some or all
of these slides in your noncommercial presentations
to colleagues or patients
When using our slides, please retain the source
attribution:
These slides may not be published, posted online, or
used in commercial presentations without permission.
Please contact permissions@clinicaloptions.com for
details
3. Faculty
Andrew Carr, MBBS, MD,
FRACP, FRCPA
Professor of Medicine
University of New South Wales
Director
HIV, Immunology, and Infectious
Disease Unit
St Vincent’s Hospital
Sydney, Australia
Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Ian M. Sanne, MBBCH, FCP(SA)
Associate Professor, Internal Medicine
and Infectious Diseases
Clinical HIV Research Unit
Department of Medicine
Faculty of Health Sciences
University of Witwatersrand
Johannesburg, South Africa
4. Disclosures
Andrew Carr, MBBS, MD, FRACP, FRCPA, has disclosed that he has
received consulting fees from Gilead Sciences, Mayne Pharma, MSD,
and ViiV Healthcare, funds for research support from Bristol-Myers
Squibb, Gilead Sciences, MSD, and ViiV Healthcare, and has served on
advisory boards for Gilead Sciences, MSD, and ViiV Healthcare.
Daniel R. Kuritzkes, MD, has disclosed that he has received consulting
fees from Bionor, CytoDyn, Gilead Sciences, GlaxoSmithKline,
InnaVirVax, Janssen, Merck, Teva, United Biopharma, and ViiV
Healthcare.
Ian M. Sanne, MBBCH, FCP(SA), has disclosed that he has received
consulting fees from Merck and funds for research support from Pfizer.
6. ARIA: DTG/ABC/3TC vs ATV + RTV +
TDF/FTC in Treatment-Naive Women
Multinational, randomized, open-label phase IIIb trial
– Primary endpoint: Wk 48 HIV-1 RNA < 50 copies/mL
Orrell C, et al. AIDS 2016. Abstract THAB0205LB. Slide credit: clinicaloptions.com
DTG/ABC/3TC QD
(n = 248)
ATV + RTV + TDF/FTC QD
(n = 247)
ART-naive women*
with HIV-1 RNA
≥ 500 copies/mL,
HLA-B*5701 negative,
and CrCl ≥ 50 mL/min
(N = 495)
Wk 48
*Women enrolled in North America, European Union, Argentina, Puerto Rico, Russian Federation,
South Africa, and Thailand.
Dosing: ATV 300 mg, RTV 100 mg, TDF/FTC 300/200 mg, DTG/ABC/3TC 50/600/300 mg.
After 48 wks, pts in the DTG/ABC/3TC arm could enter the continuation phase.
Women
who became
pregnant offered
option to enter
DTG/ABC/3TC
pregnancy study
NCT02075593
Stratified by
HIV-1 RNA ≤ or > 100,000 copies/mL,
CD4+ cell count ≤ or > 350 cells/mm3
8. ARIA: Safety Outcomes
Slide credit: clinicaloptions.comOrrell C, et al. AIDS 2016. Abstract THAB0205LB.
AE, %
DTG/ABC/3TC
(n = 248)
ATV + RTV + TDF/FTC
(n = 247)
Discontinuations due to AE 4 7
Serious AE 5 8
Fatal AE < 1* 0
Drug-related serious AE 0 1
Any AE 79 80
Grade 2-4 AE 46 55
Drug-related AE occurring
in ≥ 5% of pts in either arm
33 49
Nausea 13 14
Diarrhea 5 7
Dyspepsia 2 6
Ocular icterus 0 7
Headache 2 6
Jaundice 0 5
*1 death deemed unrelated to study drugs.
9. Randomized trial in women receiving ART or stopping ART following
pregnancy
Slide credit: clinicaloptions.com
PROMISE: Continuing vs Stopping ART in
Postpartum, Non–Breast-feeding Women
Currier J, et al. AIDS 2016. Abstract THAB0103LB.
Continue ART
(n = 827)
Stop ART*
(n = 825)
HIV-infected, ART-naive (except PMTCT)
postpartum women without guideline-
specified indication for ART, CD4+ cell
count ≥ 400 cells/mm3
, not breastfeeding
(N = 1652)
Randomized within
42 days of delivery
*Restarted ART if CD4+ cell count fell below 350 cells/mm3
or was clinically indicated.
Pts seen 4 wks post enrollment,
then every 12 wks through 84 wks
after last enrollment
Study sites: Argentina, Botswana, Brazil, China, Haiti, Peru, Thailand, and United States
Median follow-up: Continue ART arm, 2.31 yrs; Stop arm, 2.35 yrs
ART during study (Continue ART arm): 74% LPV/RTV based, 19% ATV/RTV based
10. Slide credit: clinicaloptions.com
PROMISE: Efficacy and Safety
Between treatment arms, no significant difference in primary safety or efficacy
endpoints; continuing ART associated with lower HIV event rate
Currier J, et al. AIDS 2016. Abstract THAB0103LB.
Outcome, n (Rate/100 PY) Continue ART (n = 827) Stop ART (n = 825) HR (95% CI)
Primary efficacy composite
endpoint events
4 (0.21) 6 (0.31) 0.68 (0.19-2.40)*
AIDS-defining events 2 (0.10) 3 (0.15) 0.67 (0.11-4.02)
Serious non-AIDS event 0 0 --
Death 2 (0.10) 4 (0.20) 0.52 (0.09-2.81)
Primary safety composite
endpoint events† 260 (18.4) 232 (15.4)‡
--
Composite of HIV/AIDS-related
or WHO stage 2/3 events
57 (3.09) 99 (5.49) 0.56 (0.41-0.78)
WHO stage 2/3 events 39 (2.02) 80 (4.36) 0.47 (0.32-0.68)§
189 (23%) pts in Continue ART arm experienced virologic failure; in pts with virologic
failure who had resistance testing, 52/155 (34%) had evidence of resistance
*P = .54. †
Time to first grade 3/4 sign or symptom or grade 2-4 chemistry or hematology result. ‡
P = .08.
§
P < .001.
13. STRIIVING: Switch From Suppressive ART
to Fixed-Dose DTG/ABC/3TC
Multicenter, randomized, open-label phase IIIb study
– Conducted in US, Canada, and Puerto Rico
– Primary endpoint: HIV-1 RNA < 50 copies/mL at Wk 24
Pts with HIV-1 RNA
< 50 copies/mL
on stable ART ≥ 6 mos,
no previous virologic failure, HLA-
B*5701 negative
(N = 553)
DTG/ABC/3TC
(n = 275)
Wk 48Wk 24
*Containing 2 NRTIs plus NNRTI, PI, or INSTI.
Baseline ART*
(n = 278)
DTG/ABC/3TC
(n = 244)
Slide credit: clinicaloptions.comLake J, et al. AIDS 2016. Abstract THAB0203.
14. STRIIVING: Virologic Outcomes at Wk 48
High Wk 48 rates of virologic response for early (83%) and late (92%)
switch to DTG/ABC/3TC
No cases of protocol-defined virologic failure
– 1 pt in early switch arm (< 1%) and 3 pts in post-switch BL ART arm (1%)
had HIV-1 RNA ≥ 50 c/mL at Wk 48 but all resuppressed to < 50 c/mL
Slide credit: clinicaloptions.comLake J, et al. AIDS 2016. Abstract THAB0203.
Outcome, % DTG/ABC/3TC,
Wk 24
(n = 275)
Baseline ART,
Wk 24
(n = 278)
DTG/ABC/3TC,
Wk 48
(n = 275)
Wk 24 Switch to
DTG/ABC/3TC,
Wk 24-48
(n = 244)
Virologic success (HIV-1
RNA < 50 copies/mL)
85 88 83 92
Virologic nonresponse 1 1 < 1 < 1
No virologic data 14 10 17 7
15. LATTE-2: Cabotegravir IM + Rilpivirine IM
for Long-Acting Maintenance ART
Multicenter, open-label, randomized phase IIb study
– Primary endpoints: HIV-1 RNA < 50 copies/mL at maintenance
Wk 32, PDVF, and safety
Slide credit: clinicaloptions.comMargolis DA, et al. AIDS 2016. Abstract THAB0206LB.
CAB 400 mg + RPV 600 mg IM Q4W
(n = 115)
CAB 600 mg + RPV 900 mg IM Q8W
(n = 115)
*Pts with HIV-1 RNA < 50 copies/mL from Wk 16-20 continued to maintenance phase.
†
Pts eligible for Q4W or Q8W LA extension past Wk 96.
ART-naive HIV-
infected pts younger
than
18 yrs of age with
CD4+ cell count
> 200 cells/mm3
(N = 309)
CAB 30 mg + ABC/3TC 600/300 mg PO QD
(n = 56)
CAB 30 mg +
ABC/3TC 600/
300 mg PO QD
Wk 32
Wk 20
Induction Phase* Maintenance Phase
Day 1 Wk 96†Wk 16: RPV 25 mg
PO QD added
Wk 48
16. LATTE-2: Efficacy and Safety Through
Maintenance Wk 48
Virologic efficacy of Q4W/Q8W IM
therapy similar to oral therapy
99% of ISRs for pts receiving
injectable therapy grade 1 (82%)
or 2 (17%); none grade 4
– Most frequent ISRs:
pain (67%), nodules (7%), swelling
(6%)
– Reported ISRs decreased over time
(86% Day 1, 29% Wk 48)
– 2/230 pts (< 1%) withdrew for ISRs
(both in Q8W arm)
AEs leading to withdrawal
– Pooled Q4W/Q8W IM arms, 4%
– Oral arm, 2%
Slide credit: clinicaloptions.comMargolis DA, et al. AIDS 2016. Abstract THAB0206LB
Outcome, % (n)
IM CAB +
RPV Q4W
(n = 115)
IM CAB
+ RPV
Q8W
(n = 115)
Oral CAB
+ ABC/3TC
(n = 56)
Virologic success
(HIV-1 RNA
< 50 copies/mL)
91 (105) 92 (106) 89 (50)
Virologic
nonresponse
< 1 (1) 7 (8) 2 (1)
No virologic data 8 (9) < 1 (1) 9 (5)
17. LATTE-2: Wk 48 Pt Satisfaction With IM
and PO Regimens
Slide credit: clinicaloptions.comMargolis DA, et al. AIDS 2016. Abstract THAB0206LB.
Wk 48 Patient-Reported
Outcomes, %
IM CAB + RPV
Q4W
(n = 103)
IM CAB + RPV
Q8W
(n = 109)
PO CAB +
ABC/3TC
(n = 49)
How satisfied are you with
your current treatment?
6 79 83 67
5 20 14 29
< 5 1 3 4
How satisfied would you be to
continue with your present
form of treatment?
6 85 88 55
5 13 11 33
< 5 2 1 12
Pt satisfaction assessed using 0 to 6 scoring (0 = very dissatisfied, 6 = very
satisfied)
19. Switch to DTG + RPV in Suppressed Pts
With Multiple Previous Treatment Failures
Open-label cohort study based in clinical practice setting (N = 38)
– DTG 50 mg/day + RPV 25 mg/day for pts with long-term virologic
suppression but virologic failure on > 1 previous ART regimens
HIV-1 RNA suppressed to < 35 copies/mL in 92% (35/38) at Wk 48
– No virologic failures; 3 pts d/c (GI toxicity, DDI, physician decision, n = 1)
DTG + RPV associated with improved liver function tests, improved
lipid profile, and stable kidney function at Wk 48
Slide credit: clinicaloptions.comDíaz A, et al. AIDS 2016. Abstract TUPDB0106.
Baseline Characteristic , % Switch to DTG + RPV (N = 38)
Regimen at time of switch NRTI + NNRTI + PI
NRTI + NNRTI + PI + INSTI
85
53
Reasons for switch to DTG + RPV Drug–drug interaction
Toxicity
Simplification
38
33
25
Pre-existing resistance mutations NRTI: 65; NNRTI: 37; PI: 32; INSTI: NA
20. PADDLE: Dolutegravir + Lamivudine for
Treatment-Naive Pts
Open-label, single-arm phase IV exploratory trial
18/20 pts achieved HIV-1 RNA < 50 c/mL at Wk 48
– 1 pt committed suicide (deemed unrelated to study drugs)
– 1 pt experienced PDVF at Wk 36 (BL HIV-1 RNA > 100,000 c/mL);
resuppressed HIV-1 RNA without ART change by discontinuation visit
(Wk 52)
– 3 other pts with BL HIV-1 RNA > 100,000 c/mL suppressed at Wk 48
Slide credit: clinicaloptions.comCahn P, et al. AIDS 2016. Abstract FRAB0104LB.
Treatment-naive pts
with HIV-1 RNA
> 5000-100,000 c/mL,
CD4+ cell count ≥ 200
cells/mm3
, HBsAg negative
(N = 20)
DTG 50 mg QD + 3TC 300 mg QD
(N = 20*)
*10 pts enrolled initially; additional 10 pts enrolled after confirming virologic success of first cohort at Wk 8.
†
Primary endpoint.
Wk 48†
22. Slide credit: clinicaloptions.com
MTN-020/ASPIRE: Dapivirine Vaginal Ring
for HIV Prevention in Women
Multicenter, double-blind, placebo-controlled, randomized phase III
trial in Malawi, South Africa, Uganda, and Zimbabwe
Silicone elastomer vaginal matrix ring containing NNRTI dapivirine
25 mg; ring replaced every 4 wks
Primary endpoints: efficacy and safety
HIV protection efficacy vs placebo: 27% (P = .046)
Brown E, et al. AIDS 2016. Abstract TUAC0105LB.
Baeten JM, et al. N Engl J Med. 2016;[Epub ahead of print].
Dapivirine 25 mg Vaginal Ring Q4W
+ HIV Prevention Service Package
(n = 1313)
Placebo Vaginal Ring Q4W
+ HIV Prevention Service Package
(n = 1316)
Sexually active HIV-
uninfected adult
women
(N = 2629)
≥ 1 yr; endpoint-
driven duration
23. Slide credit: clinicaloptions.com
MTN-020/ASPIRE Subcohort: Adherence
by Residual DAP Levels in Vaginal Ring
Brown E, et al. AIDS 2016. Abstract TUAC0105LB. Reproduced with permission.
Outcome Placebo Nonadherent
(≥ 23.5 mg*)
Low-High Adherence
(< 23.5 mg*)
Med-High Adherence
(< 22 mg*)
Infections, n 50 13 14 7
HIV incidence/100 PY 4.6 3.6 1.9 1.5
Risk reduction vs
PBO, % (95% CI; P
value)
--
31
(-28 to 63; .24)
56
(20 to 76; .007)
65
(22 to 84; .01)
*Residual levels of DAP remaining in returned rings.
Lower residual DAP
levels in returned rings
indicate higher
adherence
16 18 20 22 24 26 28
DAP Remaining (mg)
Expected level of ring
used for 28 days: 20-21 mg
Expected level of
unused ring: 24-25 mg
24. Sustained adherence associated with 92% reduction in risk of HIV infection
MTN-020/ASPIRE Subcohort: Adherence
vs HIV Protection 3 Mos Before Detection
No use Bottom third Top thirdMiddle third
HIVInfectionRiskReduction(%)
Slide credit: clinicaloptions.com
Adherence*
*For seroconversions, adherence level taken from visit with lowest adherence of 3 months (3 visits)
before HIV detection.
100
50
0
-50
Risk reduction
92%
(95% CI: 38 to 99)
Risk reduction
58%
(95% CI: -7 to 83)
Risk reduction
29%
(95% CI: -52 to 66)Risk reduction
11%
(95% CI: -78 to 55)
Brown E, et al. AIDS 2016. Abstract TUAC0105LB.
Reproduced with permission.
25. ATN 113: Daily Oral TDF/FTC as PrEP for
Adolescent MSM in US
Observational, open-label, single-arm feasibility study
– HIV-negative US MSM aged 15-17 yrs who demonstrated high-risk behavior for
acquiring HIV prescribed daily oral TDF/FTC; 2864 individuals prescreened, N = 79
enrolled
Wk 48 outcomes
– 3 seroconversions; all 3 had low TFV-DP drug levels at time of seroconversion
– HIV incidence: 6.41/100 PY (95% CI: 4.9-25.8)
– Median adherence declined over time for all race/ethnic groups
– Drop off in TFV-DP levels between Wk 12 and Wk 24 corresponded to reduced
frequency of scheduled study visits (from every 4 wks to every 12 wks)
Slide credit: clinicaloptions.comHosek S, et al. AIDS 2016. Abstract TUAX0104LB.
Characteristic, % Wk 4 Wk 8 Wk 12 Wk 24 Wk 36 Wk 48
TFV-DP levels > 700 fmol/punch* 60.0 52.4 55.0 31.5 22.7 28.2
*Equivalent to adherence for ≥ 4 days.
26. Slide credit: clinicaloptions.com
HVTN100: Investigational HIV-1 Vaccine
for HIV-Uninfected South African Adults
Double-blind, randomized, placebo-controlled phase I/II trial
– South African adults (N = 252) randomized to vaccination (n = 210) or placebo (n = 42)
– Vaccine: clade C ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59
– Vaccination schedule: ALVAC-HIV at mos 0 and 1; ALVAC-HIV + gp120/MF59 at mos 3, 6,
and 12 (booster)
Goal: after 6.5 mos, meet 4 prespecified immunogenetic criteria required to move into
phase IIb efficacy studies
1. Develop IgG-binding Abs to ≥ 2 of 3 gp120 vaccine antigens (LL of 95% CI ≥ 75%)
2. Exhibit noninferior IgG-binding Ab magnitude to 2 of 3 gp120 vaccine antigens vs RV144
(previous vaccine trial)
3. Exhibit noninferior response rate of Env-specific CD4+ T cells expressing IL-2, IFN-gamma, or
CD40L vs RV144 (difference within 30%)
4. Develop IgG-binding Abs to ≥ 1 clade C V1V2 Ags/tags (LL of 95% CI ≥ 56%)
All criteria met; vaccine will move into phase IIb efficacy studies
Bekker LG, et al. AIDS 2016. Abstract TUAX0102LB.
31. Prospective, randomized trial conducted in in Zimbabwe, Malawi, Uganda, and
Kenya
– Primary endpoint: mortality at 24 wks
Slide credit: clinicaloptions.com
REALITY: Enhanced OI Prophylaxis at
ART Initiation in Immunocompromised Pts
Hakim J, et al. AIDS 2016. Abstract FRAB0101LB.
Enhanced Prophylaxis
initiated at time of ART†
(n = 906)
Standard Prophylaxis
initiated at time of ART‡
(n = 899)
ART-naive HIV-infected adults
and children older than 5 yrs
of age with CD4+ cell counts
< 100 cells/mm3
(N = 1805)
Additional randomizations
conducted in factorial fashion*
*Raltegravir added to ART for 12 wks; food supplementation for 12 wks.
†
Cotrimoxazole, isoniazid/vitamin B6 300/25 mg/day for 12 wks (IPT), fluconazole 100 mg/day for
12 wks, azithromycin 500 mg/day for 5 days, albendazole 400 mg (single dose).
‡
Cotrimoxazole, IPT added after 12 wks (except in Malawi).
In both prophylaxis regimens, cotrimoxazole and IPT given at half doses if younger than 12 yrs of age.
32. Slide credit: clinicaloptions.com
REALITY: Mortality Benefit With Enhanced
OI Prophylaxis for Pts Initiating ART
1. Hakim J, et al. AIDS 2016. Abstract FRAB0101LB.
2. Kityo C, et al. AIDS 2016. Abstract FRAB0102LB.
3.3 lives saved for every 100 treated with enhanced prophylaxis[1]
Additional REALITY factorial randomization assessed mortality for
ART initiation with 2 NRTIs + NNRTI + RAL vs 2 NRTIs + NNRTI[2]
– Addition of RAL to standard 3-drug ART did not affect all-cause mortality
at 24 or 48 wks
Deaths, %[1]
Enhanced
Prophylaxis
(n = 906)
Standard
Prophylaxis
(n = 899)
HR
(95% CI)
P Value
Wk 24* 8.9 12.2
0.73
(0.54-0.97)
.03
Wk 48 11.0 14.4
0.75
(0.58-0.98)
.04
*Primary endpoint.
33. Slide credit: clinicaloptions.com
REALITY: Additional Outcomes Favor
Enhanced OI Prophylaxis
Hakim J, et al. AIDS 2016. Abstract FRAB0101LB.
Reproduced with permission.
WHO stage 4 disease or death
WHO stage 3/4 disease or death
New TB disease
AE causing OI drug modification
Hospitalizations
New cryptococcal disease
New candida disease
Presumptive severe bacterial infection
Grade 4 AE
Serious AE
Grade 3/4 AE
Grade 4 AE definitely/probably related to prophylaxis
Grade 4 AE definitely/probably/possibly related to prophylaxis
Favors Enhanced Prophylaxis Favors Standard Prophylaxis
.006
.007
.01
.01
.02
.04
.06
.07
.35
.21
.60
.21
.97
0.3 0.5 0.7 1.0 1.5 2.0
HR (Enhanced Prophylaxis:Standard Prophylaxis)
P Value
34. Multicenter, open-label, randomized phase III trial
– Pts in Benin, Guinea, and Senegal
– Primary outcome: mortality at 12 mos post-randomization
Slide credit: clinicaloptions.com
RAFA: ART With Standard- vs High-Dose
Rifampicin in HIV/TB-Coinfected Pts
Merle CS, et al. AIDS 2016. Abstract WEAB0205LB.
Pactr.org. PACTR201105000291300. EDCTP Project Portfolio.
Standard-Dose Rifampicin,†
Start ART at Wk 8
(n = 258)
Standard-Dose Rifampicin,†
Start ART at Wk 2
(n = 262)
ART-naive
HIV/TB-coinfected
adults with CD4+
cell count ≥ 50
cells/mm3
(N = 778)
High-Dose Rifampicin,* Start ART at Wk 8
(n = 258)
*Rifampicin 15 mg/kg plus ethambutol, isoniazid, pyrazinamide.
†
Rifampicin 10 mg/kg plus ethambutol, isoniazid, pyrazinamide.
ART regimen: EFV 600 mg + 2 NRTIs.
All pts received
rifampicin 10 mg/kg
+ isoniazid
Intensive Phase Continuation PhaseWk 8
35. Slide credit: clinicaloptions.com
RAFA: Survival Outcomes With High- vs
Standard-Dose Rifampicin
Overall survival not improved, but high-dose rifampicin may benefit severely
immunocompromised pts
Merle CS, et al. AIDS 2016. Abstract WEAB0205LB.
Reproduced with permission.
Overall Survival, %
HD RIF, ART Wk 8
(n = 249)
SD RIF, ART Wk 8
(n = 247)
SD RIF, ART Wk 2
(n = 251)
12 mos 90 86 89
18 mos 90 85 88
Mortality for Pts With CD4+ Cell Count < 100 cells/mm3
(n = 159)
SD RIF, ART Wk 8 (n = 47)
SD RIF, ART Wk 2 (n = 60)
HD RIF, ART Wk 8 (n = 52)
HD RIF vs SD RIF, ART Wk 2:
HR: 0.20 (95% CI: 0.04-0.90)
HD RIF vs SD RIF, ART Wk 8:
HR: 0.12 (95% CI: 0.03-0.55)
1.00
0.75
0.50
0.25
0
0 2 4 6 8 10 12 14 16 18
Mos Since Randomization
Survival
37. ANRS 12249: Test and Treat Strategies in
Rural South Africa (KwaZulu-Natal)
Test and treat trial; treatment cluster-randomized by site
– Rapid HIV testing during home visits every 6 mos; if HIV infected, pts
moved to randomized treatment
Similar HIV incidence between randomized groups
Slide credit: clinicaloptions.comIwuji C, et al. AIDS 2016. Abstract FRAC0105LB.
Intervention Arm
Immediate ART
(n = 13,236)
Control Arm (Guideline-Based ART)
ART if CD4+ cell count ≤ 350/500 cells/mm3
* or stage WHO 3/4
(n = 14,917)
HIV-infected adults
(N = 28,153)
Outcome Intervention Control Adjusted RR P Value
Mean HIV prevalence, % 30 31 -- --
12-mo linkage to care for HIV-
infected pts,†
% 47 47 -- --
HIV incidence/100 PY 2.13 2.27 0.95 .5821
*Guidelines for ART initiation cutoff changed during study. †
Pts not previously receiving care.
38. FORTH: HIV Self-Testing in Australian
MSM
HIV-uninfected Australian MSM who had > 5 male partners or condomless anal
intercourse in past 3 mos (N = 362) randomized to free access to HIV self-testing
(n = 182) or standard care (n = 180)
Slide credit: clinicaloptions.comJamil MS, et al. AIDS 2016. Abstract FRAC0102. Reproduced with permission.
5.0
1.0
0
MeanHIVTests/Yr
3.0
2.0
4.0
Self-testing
(n = 178)
Standard care
(n = 165)
Self-testing
(n = 148)
Standard care
(n = 141)
Self-testing
(n = 30)
Standard care
(n = 24)
Overall Recent HIV Test at BL
(≤ Last 2 Yrs)
Nonrecent HIV Test at BL
(> Last 2 Yrs)
Self tests
Facility-based testing
RR: 2.1 (P < .001)
RR: 2.0 (P < .001)
RR: 3.95 (P < .001)
1.7 1.9 1.8 2.1
0.8 0.7
2.4
2.4
2.1
No decline in STI testing for self-testing group vs standard care group
39. Further Studies Assessing HIV Testing
Strategies
Strategies to improve male HIV testing for those in relationships in Kenya[1]
– Pregnant or postpartum women with male HIV-uninfected or HIV-unknown partners
randomized to groups in which they gave partner an HIV self-test (HIVST group,
n = 284) or HIV clinic referral voucher (comparison group, n = 286)
Slide credit: clinicaloptions.com
1. Agot K, et al. AIDS 2016. Abstract FRAC0104.
2. Patel VV, et al. AIDS 2016. Abstract FRAC0101.
Outcome, n (%) HIVST Comparison Difference, % (95% CI)
Male partner testing 258 (90.8) 148 (51.7) 39.1 (32.4 to 45.8)
Discuss HIV testing 271 (95.4) 276 (96.5) -1.1 (-4.3 to 2.2)
Couples testing 214 (75.4) 95 (33.2) 42.1 (34.7 to 49.6)
Learned partner’s HIV status 255 (89.8) 145 (50.7) 39.1 (32.3 to 45.9)
Partner violence due to testing 1 (0.4) 1 (0.3) 0.0 (-1.0 to 1.0)
CHALO: e-messaging reminders for HIV testing for MSM in India[2]
– Of pts who completed follow-up (N = 130), intervention increased recent HIV testing
vs baseline (44% vs 32%; P < .05); “avoidance” language emphasizing negative
outcomes was associated with higher rate of testing or intention to test vs
“approach” language highlighting a benefit (82% vs 65%, P =.03)
40. Validation of Cepheid GeneXpert HIV-1 Quant for monitoring HIV-1
RNA in pts on ART[1]
– Point-of-care, PCR-based testing system
– Compared with Abbott Real Time HIV-1 assay,
LAg-Avidity for detecting viral breakthrough for pts on ART[2]
Studies Assessing Tools for Monitoring
ART Efficacy and Failure
Slide credit: clinicaloptions.com
1. Kulkarni S, et al. AIDS 2016. Abstract THPDB0205. 2. Nicholas S, et al. AIDS
2016. Abstract THPEB046. 3. Wendel SK, et al. AIDS 2016. Abstract THPEB039.
Study Findings
Validation of GeneXpert HIV-1 Quant for
monitoring HIV-1 RNA in pts on ART[1]
Point-of-care, PCR-based testing system
Assessed samples from Indian pts with varying
HIV-1 RNA levels (N = 219) and controls
Similar detection with GeneXpert
vs standard Real Time assay:
R2
= 0.784
Sensitivity/specificity for detecting
HIV-1 RNA > 200 c/mL: 97%/100%
Assessment of SAMBA-1 for routine
monitoring of HIV-1 RNA in pts on ART[2]
Nearly point-of-care, PCR-based testing system
Assessed pts on first-line ART at hospital/health
centers in Malawi from Aug 2013 to Dec 2015
13675/19036 (72%) received ≥ 1 test
> 80% of tests reviewed the same day
at health centers
LAg-Avidity for detecting viral breakthrough
for pts on ART[3]
Antigen avidity enzyme immunoassay
Assessed samples from US pts pre/post ART
(n = 72) and suppressed pts who had
breakthrough (n = 179)
Sensitivity/specificity for detecting
viral breakthrough: 65%/86%
41. Go Online for More CCO
Coverage of AIDS 2016!
Capsule Summaries of all the key data
CME-certified text module with expert
faculty commentary on all the key studies
clinicaloptions.com/HIV
Editor's Notes
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the authors of the CCO material, not those of Clinical Care Options, LLC, the CME providers, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
This slide lists the faculty who were involved in the production of these slides.
This slide lists the disclosure information of the faculty and staff involved in the development of these slides.
3TC, lamivudine; ABC, abacavir; ATV, atazanavir; CrCl, creatinine clearance; DTG, dolutegravir; FTC, emtricitabine; QD, once daily; RTV, ritonavir; TDF, tenofovir.
For more information about this study, go to http://www.clinicaloptions.com/HIV/Conference%20Coverage/AIDS%202016/Highlights/Capsules/THAB0205LB.aspx
3TC, lamivudine; ABC, abacavir; ATV, atazanavir; DTG, dolutegravir; FTC, emtricitabine; ITT-E, intent-to-treat exposed; RTV, ritonavir; TDF, tenofovir.
For more information about this study, go to http://www.clinicaloptions.com/HIV/Conference%20Coverage/AIDS%202016/Highlights/Capsules/THAB0205LB.aspx
3TC, lamivudine; ABC, abacavir; AE, adverse event; ATV, atazanavir; DTG, dolutegravir; FTC, emtricitabine; RTV, ritonavir; TDF, tenofovir.
For more information about this study, go to http://www.clinicaloptions.com/HIV/Conference%20Coverage/AIDS%202016/Highlights/Capsules/THAB0205LB.aspx
ART, antiretroviral therapy; ATV, atazanavir; LPV, lopinavir; PMTCT, prevention of mother-to-child transmission; RTV, ritonavir.
For more information about this study, go to http://www.clinicaloptions.com/HIV/Conference%20Coverage/AIDS%202016/Highlights/Capsules/THAB0103LB.aspx
ART, antiretroviral therapy; PY, patient-years; WHO, World Health Organization.
For more information about this study, go to http://www.clinicaloptions.com/HIV/Conference%20Coverage/AIDS%202016/Highlights/Capsules/THAB0103LB.aspx
ART, antiretroviral therapy; BID, twice daily; FTC, emtricitabine; QD, once daily; RAL, raltegravir; TDF, tenofovir.
For more information about this study, go to http://www.clinicaloptions.com/HIV/Conference%20Coverage/AIDS%202016/Highlights/Capsules/FRAB0103LB.aspx
BID, twice daily; BL, baseline; FTC, emtricitabine; QD, once daily; RAL, raltegravir; TDF, tenofovir.
For more information about this study, go to http://www.clinicaloptions.com/HIV/Conference%20Coverage/AIDS%202016/Highlights/Capsules/FRAB0103LB.aspx
3TC, lamivudine; ABC, abacavir; CAB, cabotegravir; IM, intramuscular; PO, oral; Q4W, every 4 weeks; Q8W, every 8 weeks.
ART, antiretroviral therapy; d/c, discontinued; DDI, drug–drug interaction; DTG, dolutegravir; GI, gastrointestinal; NA, not available; RPV, rilpivirine.
For more information about this study, go to http://www.clinicaloptions.com/HIV/Conference%20Coverage/AIDS%202016/Highlights/Capsules/TUPDB0106.aspx
3TC, lamivudine; ART, antiretroviral therapy; BL, baseline; DTG, dolutegravir; HBsAg, hepatitis B virus surface antigen; PDVF, protocol-defined virologic failure; QD, once daily.
For more information about this study, go to http://www.clinicaloptions.com/HIV/Conference%20Coverage/AIDS%202016/Highlights/Capsules/FRAB0104LB.aspx
Q4W, every 4 weeks.
DAP, dapivirine; PBO, placebo; PY, patient-years.
DBS, dried blood spot; FTC, emtricitabine; MSM, men who have sex with men; PrEP, pre-exposure prophylaxis; PY, patient-years; TDF, tenofovir DF; TFV-DP, tenofovir diphosphate.
For more information about this study, go to http://www.clinicaloptions.com/HIV/Conference%20Coverage/AIDS%202016/Highlights/Capsules/TUAX0104LB.aspx
BL, baseline; DSV, dasabuvir; GT, genotype; HCV, hepatitis C virus; ITT, intent to treat; LDV, ledipasvir; LTFU, lost to follow-up; OBV, ombitasvir; PTV, paritaprevir; RBV, ribavirin; RTV, ritonavir; SOF, sofosbuvir; SVR, sustained virologic response.
ART, antiretroviral therapy; IPT, isoniazid preventive therapy; OI, opportunistic infection.
For more information about this study, go to http://www.clinicaloptions.com/HIV/Conference%20Coverage/AIDS%202016/Highlights/Capsules/FRAB0101LB.aspx
ART, antiretroviral therapy; OI, opportunistic infection; RAL, raltegravir.
For more information about this study, go to http://www.clinicaloptions.com/HIV/Conference%20Coverage/AIDS%202016/Highlights/Capsules/FRAB0101LB.aspx AND
http://www.clinicaloptions.com/HIV/Conference%20Coverage/AIDS%202016/Highlights/Capsules/FRAB0102LB.aspx
AE, adverse event; OI, opportunistic infection; TB, tuberculosis; WHO, World Health Organization.
For more information about this study, go to http://www.clinicaloptions.com/HIV/Conference%20Coverage/AIDS%202016/Highlights/Capsules/FRAB0101LB.aspx